I'm late to the party. This performance-enhancing drug has been banned as a prohibited substance by WADA effective January 1, 2023.
Volelotor (trade name Oxbryta) is a first-in-class medication for the treatment of sickle cell disease (and resulting hemolytic anemia).
It was approved by the US FDA in November 2019. It was approved in the EU in February 2022.
"Oxbryta, voxelotor, works by improving the ability of the haemoglobin to hold on to oxygen, and preventing it from forming chains. This helps the red blood cells to maintain normal shape and flexibility, reducing their excess breakdown and improving their lifespan."
www.ema.europa.eu
Volelotor (trade name Oxbryta) is a first-in-class medication for the treatment of sickle cell disease (and resulting hemolytic anemia).
It was approved by the US FDA in November 2019. It was approved in the EU in February 2022.
"Oxbryta, voxelotor, works by improving the ability of the haemoglobin to hold on to oxygen, and preventing it from forming chains. This helps the red blood cells to maintain normal shape and flexibility, reducing their excess breakdown and improving their lifespan."
Oxbryta | European Medicines Agency (EMA)
